NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial.

ABSTRACT:

Objective

The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group.

Methods

There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups.

Results

The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pr

SUBMITTER: Gao M 

PROVIDER: S-EPMC12913733 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature